ALVAC-CEA vaccine
ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.[1]
A phase I trial in 118 patients showed safety in humans.[2]
References
[edit]- ^ "NCI Drug Dictionary". Comprehensive Cancer Information. Retrieved 2024-07-02.
- ^ Kaufman, Howard L.; Lenz, Heinz-Josef; Marshall, John; Singh, Deepti; Garett, Chris; Cripps, Christine; Moore, Malcolm; von Mehren, Margaret; Dalfen, Richard; Heim, William J.; Conry, Robert M.; Urba, Walter J.; Benson, Al B.; Yu, Maria; Caterini, Judy; Kim-Schulze, Seunghee; Debenedette, Mark; Salha, Danielle; Vogel, Thorsten; Elias, Ileana; Berinstein, Neil L. (2008). "Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer". Clinical Cancer Research. 14 (15): 4843–4849. doi:10.1158/1078-0432.CCR-08-0276. PMID 18676757. S2CID 18152383.
External links
[edit]- ALVAC-CEA vaccine entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |